Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations, Visual Field (VF) and Spectral Domain Optical Coherence Tomography (SD-OCT) [ Time Frame: Days 0 and 7, and Month 1 to 6 ] [ Designated as safety issue: Yes ]

Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluation intraocular pressure (IOP) [ Time Frame: Screening, Days 0 (before injection, both eyes; after injection study eye only), 1 and 7, and Month 1 to 6 ] [ Designated as safety issue: Yes ]

Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluation, Fundus Photographs (FP) [ Time Frame: Days 0 and 7, and Month 4 ] [ Designated as safety issue: Yes ]

Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations optic nerve head stereo photographs and contrast sensitivity [ Time Frame: Days 0 and 7, and Month 4 and 6 ] [ Designated as safety issue: Yes ]

Safety and tolerability of a single IVT dose of QPI-1007 as assessed by use of concomitant treatments [ Time Frame: Days 0, 1 and 7, and Month 1 to 6 ] [ Designated as safety issue: Yes ]

QPI-1007 pharmacokinetics (PK) parameters as assessed by the peak plasma concentration (Cmax) [ Time Frame: Pre-injection, 1, 4 and 24 hours after injection, and 7 days after injection ] [ Designated as safety issue: No ]

QPI-1007 pharmacokinetics (PK) parameters as assessed by the time to peak plasma concentration (Tmax) [ Time Frame: Pre-injection, 1, 4 and 24 hours after injection, and 7 days after injection ] [ Designated as safety issue: No ]

Difference between QPI-1007 and control group (sham) as assessed by the prevalence of the abnormal visual fields [ Time Frame: 4 months after injection ] [ Designated as safety issue: No ]

Difference between QPI-1007 and control group (sham) as assessed by change in the mean deviation compared to baseline [ Time Frame: 4 months after injection ] [ Designated as safety issue: No ]

Difference between QPI-1007 and control group (sham) as assessed by progression of the visual fields compared to baseline [ Time Frame: 4 months after injection ] [ Designated as safety issue: No ]

Difference between QPI-1007 and control group (sham) as assessed by change in the mean BCVA using the EDTRS chart compared to baseline [ Time Frame: 4 months after injection ] [ Designated as safety issue: No ]

Difference between QPI-1007 and control group (sham) as assessed by SD-OCT parameters [ Time Frame: 4 months after injection ] [ Designated as safety issue: No ]

Difference between QPI-1007 and control group (sham) as assessed by change in the mean contrast sensitivity compared to baseline [ Time Frame: 4 months after injection ] [ Designated as safety issue: No ]

This study will assess any side effects that may occur when QPI-1007 is injected into the eye in subjects with acute primary angle-closure glaucoma, as well as how long it takes for the body to clear the drug. This study will also test whether QPI-1007, injected into the eye, helps prevent both structural damage of the nerve tissue in the eye and the loss of visual function in subjects with acute primary angle-closure glaucoma.

Detailed Description

This is a Phase IIa double-masked, single dose, randomized, sham-controlled study evaluating the safety and tolerability, and pharmacokinetics of QPI-1007 versus Control (sham procedure) in subjects with an acute attack of primary angle-closure glaucoma.

Subjects will be randomized at a ratio of 1:1 into one of two study arms: 1.5 QPI-1007 arm or Control arm (sham procedure). The study will enroll approximately 30 subjects into each arm. Randomization will be stratified by time from symptom onset to the study drug administration or sham procedure (≤72 hours and >72 hours).